The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 12, 2017
Filed:
Jun. 03, 2015
Applicant:
University of Maryland, Baltimore, Baltimore, MD (US);
Inventors:
Alan E. Tomkinson, Albuquerque, NM (US);
Helen Xi Chen, Austin, TX (US);
Barbara Dziegielewska, Charlottesville, VA (US);
Alexander D. Mackerell, Baltimore, MD (US);
Shijun Zhong, Catonsville, MD (US);
Gerald M. Wilson, Middle River, MD (US);
Assignee:
University of Maryland, Baltimore, Baltimore, MD (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/165 (2006.01); A61K 31/505 (2006.01); C40B 30/02 (2006.01); G06F 19/16 (2011.01); A61K 31/166 (2006.01); A61K 31/255 (2006.01); A61N 5/10 (2006.01); G01N 21/64 (2006.01); G06F 19/00 (2011.01); A61K 31/397 (2006.01); C07D 307/68 (2006.01); A61K 31/175 (2006.01); A61K 31/341 (2006.01); A61K 31/404 (2006.01); A61K 31/41 (2006.01); A61K 31/4184 (2006.01); A61K 31/423 (2006.01); A61K 31/4245 (2006.01); A61K 31/428 (2006.01); A61K 31/433 (2006.01); A61K 31/436 (2006.01); A61K 31/4439 (2006.01); A61K 31/495 (2006.01); A61K 31/553 (2006.01); A61K 45/06 (2006.01); C07D 209/30 (2006.01); C07D 235/28 (2006.01); C07D 257/04 (2006.01); C07D 263/58 (2006.01); C07D 267/18 (2006.01); C07D 271/12 (2006.01); C07D 277/74 (2006.01); C07D 285/14 (2006.01); C07D 401/12 (2006.01); C07D 407/12 (2006.01);
U.S. Cl.
CPC ...
A61K 31/505 (2013.01); A61K 31/165 (2013.01); A61K 31/166 (2013.01); A61K 31/175 (2013.01); A61K 31/255 (2013.01); A61K 31/341 (2013.01); A61K 31/397 (2013.01); A61K 31/404 (2013.01); A61K 31/41 (2013.01); A61K 31/4184 (2013.01); A61K 31/423 (2013.01); A61K 31/428 (2013.01); A61K 31/4245 (2013.01); A61K 31/433 (2013.01); A61K 31/436 (2013.01); A61K 31/4439 (2013.01); A61K 31/495 (2013.01); A61K 31/553 (2013.01); A61K 45/06 (2013.01); A61N 5/10 (2013.01); C07D 209/30 (2013.01); C07D 235/28 (2013.01); C07D 257/04 (2013.01); C07D 263/58 (2013.01); C07D 267/18 (2013.01); C07D 271/12 (2013.01); C07D 277/74 (2013.01); C07D 285/14 (2013.01); C07D 307/68 (2013.01); C07D 401/12 (2013.01); C07D 407/12 (2013.01); C40B 30/02 (2013.01); G01N 21/64 (2013.01); G06F 19/16 (2013.01); G06F 19/706 (2013.01);
Abstract
Methods for treating cancer using compounds that inhibit human DNA ligases. Methods for using compounds that inhibit human DNA ligases to provide insights into the reaction mechanisms of human DNA ligases, for example to identify the human DNA ligase involved in different DNA repair pathways. Screening methods for compounds that inhibit human DNA ligases.